Ubs Group Ag Pro Phase Labs, Inc. Transaction History
Ubs Group Ag
- $611 Billion
- Q3 2025
A detailed history of Ubs Group Ag transactions in Pro Phase Labs, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 19,740 shares of PRPH stock, worth $5,922. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,740
Previous 57,670
65.77%
Holding current value
$5,922
Previous $22,000
63.64%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding PRPH
# of Institutions
30Shares Held
2.98MCall Options Held
13.7KPut Options Held
0-
Sykon Capital LLC Harrison, NY645KShares$193,4380.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA532KShares$159,5750.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA398KShares$119,3740.0% of portfolio
-
Geode Capital Management, LLC Boston, MA303KShares$90,8780.0% of portfolio
-
Accretive Wealth Partners, LLC Parsippany, NJ250KShares$75,0000.04% of portfolio
About ProPhase Labs, Inc.
- Ticker PRPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 16,024,400
- Market Cap $4.81M
- Description
- ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...